Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and effects of FB-102 in healthy adult volunteers aged 18 to 60 years in this Phase 1 clinical trial. The study aims to understand how FB-102 behaves in the body and how the immune system responds after single and multiple doses. It compares FB-102 with a placebo under controlled conditions. FB-102 is given in three parts Part A involves a single dose Part B provides weekly doses for four weeks Part C gives doses every two weeks for four doses. Participants may also join an optional extension period lasting about 15 weeks, during which no drug is given but blood samples and safety monitoring continue. Participants will undergo various assessments including blood tests to measure drug levels and immune responses, as well as monitoring for any adverse effects from day 1 through Day 85. Safety, tolerability, and pharmacokinetics are the main focus. The total involvement spans several months, including dosing and follow-up to ensure thorough evaluation of FB-102.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the effect of olpasiran compared to a placebo on the risk of coronary heart disease death, heart attack, or urgent coronary revascularization in people at risk for a first major cardiovascular event who have elevated lipoproteina levels. This phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study is designed as a double-blind, placebo-controlled trial, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period spans up to approximately 6.2 years, during which participants receive regular injections and monitoring. Throughout the study, participants will be assessed for the time until coronary heart disease death, myocardial infarction, or urgent coronary revascularization occurs. Additional measurements include changes in lipoproteina levels and monitoring of cardiovascular events, strokes, and safety through adverse event tracking. Participants will have regular evaluations over the treatment duration, ensuring close follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effects of olpasiran, compared to a placebo, on the volume of non-calcified plaque in participants with stable atherosclerotic cardiovascular disease and elevated lipoproteina. This Phase 3 trial aims to study how olpasiran impacts coronary artery plaque burden using Coronary Computed Tomography Angiography CCTA. The study is sponsored by Amgen and includes adults aged 35 to 80 years with a history of coronary artery disease and elevated lipoproteina levels. Participants are randomly assigned to receive either olpasiran or placebo administered as a subcutaneous injection every 12 weeks. The trial lasts for 72 weeks during which changes in non-calcified plaque volume will be measured from baseline to week 72. Secondary outcomes include changes in low attenuation plaque volume, total plaque volume, calcified plaque volume, and monitoring of treatment-emergent adverse events up to week 74. Throughout the study, participants will undergo regular assessments including CCTA scans to measure plaque volumes. Safety and tolerability will be closely monitored by tracking adverse events. The primary outcome focuses on the change in non-calcified plaque volume over the 72-week treatment period. Participants can expect scheduled visits for injections and imaging assessments, with the entire trial lasting approximately 18 months.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 2b study to evaluate the safety, immune response, and effectiveness of a new bivalent protein vaccine against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV in adults aged 60 years and older. This randomized, placebo-controlled, observer-blind trial aims to prevent lower respiratory tract diseases caused by these viruses in an elderly population. The study is sponsored by Sanofi and focuses on vaccine prevention in healthy volunteers. Participants will receive a single intramuscular injection of either the bivalent RSVHMPV protein vaccine or a matching placebo. The study includes an initial Safety Lead-in Cohort of 200 participants randomized 11 to vaccine or placebo, followed by a Main Cohort of 7,800 participants also randomized 11 after safety review. Both groups receive only one dose and are monitored over time to assess vaccine effects and safety. Throughout the study, participants will be monitored for respiratory infections caused by RSV and HMPV from 14 days up to 12 months after vaccination. Researchers will also evaluate immune responses by measuring antibody levels before vaccination and at multiple time points afterward. Safety assessments include tracking adverse events immediately after vaccination and for up to one year. The total participation duration spans about 12 months, covering vaccination, follow-up visits, and safety monitoring.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of HB-1 compared to a placebo in adults aged 18 to 65 years diagnosed with Post-Traumatic Stress Disorder PTSD. This phase 2, multi-center, randomized, double-blind, placebo-controlled trial will include approximately 200 to 500 participants without severe neuropsychiatric or medical conditions. The study aims to better understand how HB-1 affects PTSD symptoms using established clinical assessments. Participants will receive HB-1, a dual active pharmaceutical ingredient tablet containing telmisartan and verapamil extended release, or a matching placebo. They will start with a lower dose of HB-1 taken once daily and may have their dose increased at Week 4 or Week 8 if symptoms have not sufficiently improved and no serious side effects have occurred. Treatment will continue for 12 weeks, followed by a safety follow-up one week after the last dose. Throughout the study, participants will attend visits at baseline, Week 4, Week 8, and Week 12 for symptom assessments using several clinical scales and questionnaires. Safety monitoring will include checking for adverse events, vital signs, ECGs, and lab tests. The primary outcome is the change in clinician-rated PTSD symptoms. The total participation time is about 13 weeks including treatment and follow-up.
1-10 of 13
1